<DOC>
	<DOCNO>NCT00956449</DOCNO>
	<brief_summary>The purpose study evaluate antibody response three influenza vaccine strain include licensed seasonal flu vaccine , measure hemagglutination inhibition ( HI ) 21 day post immunization non−elderly elderly subject compliance requirement current European Union ( EU ) recommendation evaluation immunogenicity new formulation license flu vaccine ( CPMP/BWP/214/96 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Influenza Vaccine ( Surface Antigen , Inactivated ) Ph.Eur , Formulation 2009-2010 , When Administered Non-Elderly Adult Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects eligible enrollment study male female adult : ≥ 18 year age , mentally competent , willing able give inform consent prior study entry ; able comply study requirement ; good health determine : 1. medical history , 2. physical examination , 3. clinical judgment investigator . Subjects enrol study least one follow criterion fulfil : They serious chronic acute disease ( judgment investigator ) include limit : 1 . Cancer , except localize skin cancer 2 . Advanced congestive heart failure 3 . Chronic obstructive pulmonary disease ( COPD ) 4 . Autoimmune disease ( include rheumatoid arthritis ) 5 . Acute progressive hepatic disease 6 . Acute progressive renal disease 7 . Severe neurological psychiatric disorder 8 . Severe Asthma History anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study vaccine ( e.g. , egg , chicken protein , chicken feather , influenza viral protein neomycin polymyxin ) . Known suspected ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) result example : 1. receipt immunosuppressive therapy ( parental oral cortical steroid cancer chemotherapy/radiotherapy ) within past 60 day full length study ; 2 . Receipt immunostimulants , 3 . Receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within past 3 month full length study , 4 . Suspected known HIV infection HIVrelated disease . Known suspected history drug alcohol abuse . They bleed diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject ; Women pregnant woman childbearing potential unwilling practice acceptable contraception duration study ( 21 day ) . Females pregnant nursing ( breastfeed ) mother females childbearing age plan use acceptable birth control measure , duration study . Adequate contraception define hormonal ( oral , injection , transdermal patch , implant , cervical ring ) , barrier ( condom diaphragm ) , intrauterine device ( IUD ) monogamous relationship vasectomize partner vasectomize 6 month prior subject 's study entry . Influenza vaccination laboratory confirm influenza within last 6 month one influenza vaccination within past 12 month Within past 4 week receive : another vaccine investigational agent . Any acute chronic infection require systemic antibiotic treatment antiviral therapy within last 7 day . They experience fever ( i.e. , axillary temperature ≥ 38°C ) within last 3 day Simultaneous participation another clinical study . Any condition , , opinion investigator , might prevent subject participation interfere evaluation study objective . Severely obese Body Mass Index ( BMI ) &gt; 35 Site personnel involve evaluation safety immediate relative exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>flu</keyword>
	<keyword>influenza</keyword>
	<keyword>seasonal influenza</keyword>
	<keyword>influenza vaccine antigen</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>antibody response</keyword>
	<keyword>intra muscular</keyword>
	<keyword>elderly</keyword>
	<keyword>non-elderly</keyword>
</DOC>